RaQualia Pharma Inc.
TSE:4579.T
562 (JPY) • At close September 19, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | RaQualia Pharma Inc. |
Symbool | 4579.T |
Munteenheid | JPY |
Prijs | 562 |
Beurswaarde | 12,160,679,078 |
Dividendpercentage | 0% |
52-weken bereik | 479 - 943 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Hirobumi Takeuchi |
Website | https://www.raqualia.co.jp |
An error occurred while fetching data.
Over RaQualia Pharma Inc.
RaQualia Pharma Inc. engages in the research and development of pharmaceutical compounds worldwide. Its human products portfolio includes tegoprazan for gastroesophageal reflux disease, which is in phase 1 clinical trial in the United States; and grapiprant for pain management, which is in phase II clinical trial in the United States
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (JPY)
Cijfers zijn in miljoenen (JPY)